As the development race for antibody-based pharmaceuticals intensifies, manufacturers are constantly looking to develop new pipelines to market ahead of the competition. The speed of development of antibody-based biopharmaceuticals depends mainly on establishing a production process, production of investigational drugs, andthe ever-present challenge of improving production capacity. We talk to a major manufacturer of
pharmaceuticals in Japan to discover the steps they are taking to speed up their production process.
Download the full article.
November 19, 2015